Get started
Viridian Therapeutics, Inc.Viridian Therapeutics, Inc.Viridian Therapeutics, Inc.

Viridian Therapeutics, Inc.

No trades
See on Supercharts
OverviewFinancialsNewsIdeasDiscussionsForecastSeasonalsETFs

VRDN chart


Full chart

VRDN upcoming earnings


Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪1.59 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−4.27 USD
Net income (FY)
‪−208.56 M‬ USD
Revenue (FY)
‪302.00 K‬ USD
Shares float
‪73.55 M‬
Beta (1Y)
1.08

Employees


Employees (FY)
143
Change (1Y)
+47 +48.96%
Revenue / Employee (1Y)
—
Net income / Employee (1Y)
—

About Viridian Therapeutics, Inc.


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Stephen Frank Mahoney
Website
viridiantherapeutics.com
Headquarters
Waltham
Founded
2006
ISIN
US92790C1045
FIGI
BBG002H242Z5
Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Check out other big names from the same industry as VRDN.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

VRDN news



Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

Frequently Asked Questions


Depending on the exchange, the stock ticker may vary. For instance, on BOATS exchange Viridian Therapeutics, Inc. stocks are traded under the ticker VRDN.
We've gathered analysts' opinions on Viridian Therapeutics, Inc. future price: according to them, VRDN price has a max estimate of 61.00 USD and a min estimate of 26.00 USD. Watch VRDN chart and read a more detailed Viridian Therapeutics, Inc. stock forecast: see what analysts think of Viridian Therapeutics, Inc. and suggest that you do with its stocks.
VRDN reached its all-time high on Oct 1, 2024 with the price of 23.40 USD, and its all-time low was 10.86 USD and was reached on Apr 8, 2025. View more price dynamics on VRDN chart.
See other stocks reaching their highest and lowest prices.
Yes, you can track Viridian Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Viridian Therapeutics, Inc. is going to release the next earnings report on Nov 18, 2025. Keep track of upcoming events with our Earnings Calendar.
VRDN earnings for the last quarter are −1.00 USD per share, whereas the estimation was −1.01 USD resulting in a 0.92% surprise. The estimated earnings for the next quarter are −0.95 USD per share. See more details about Viridian Therapeutics, Inc. earnings.
Viridian Therapeutics, Inc. revenue for the last quarter amounts to ‪75.00 K‬ USD, despite the estimated figure of ‪50.92 K‬ USD. In the next quarter, revenue is expected to reach ‪37.30 K‬ USD.
VRDN net income for the last quarter is ‪−100.73 M‬ USD, while the quarter before that showed ‪−86.91 M‬ USD of net income which accounts for −15.90% change. Track more Viridian Therapeutics, Inc. financial stats to get the full picture.
No, VRDN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 23, 2025, the company has 143 employees. See our rating of the largest employees — is Viridian Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Viridian Therapeutics, Inc. EBITDA is ‪−370.50 M‬ USD, and current EBITDA margin is ‪−98.61 K‬%. See more stats in Viridian Therapeutics, Inc. financial statements.
Like other stocks, VRDN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Viridian Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.